Skip to main content
. 2018 May 18;18(2):135–147. doi: 10.3727/105221618X15174108894682

Figure 6.

Figure 6

EMD1214063 does not impact inflammation or fibrosis at 8 weeks or 11 weeks of treatment of Met-β-catenin mice. (A) IHC for CD45 shows comparable inflammatory cells both within and outside the tumor foci at 8 weeks or 11 weeks in controls or EMD1214063 treatment group. (B) Sirius Red staining shows lack of any hepatic fibrosis in control-treated Met-β-catenin mice at either 8 or 11 weeks. No differences between controls and EMD1214063 treatment were evident at either time points.